🇺🇸 FDA
Pipeline program

Revatio 0.8 mg/ml solution for injection

APHP180603

Phase 3 small_molecule active

Quick answer

Revatio 0.8 mg/ml solution for injection for Hypoxic ischemic encephalopathy is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Hypoxic ischemic encephalopathy
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials